Ticker

Globally recognized leader in early-phase oncology clinical development and experimental therapeutics Strengthens strategic expertise as Akari advances its novel ADC payload that modulates RNA splicing into future Phase 1 First-in-Human trial TAMPA, Fla. and LONDON, July 07, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs)…

Consolidated closing of recently announced $5.5 million PIPE led by existing investors, combined with an additional $2.8 million in proceeds from warrant exercises, results in approximately $8.3 million of capital received in Q2 2026, supporting future potential value inflection points Consolidated closing of recently announced $5.5 million PIPE led by existing investors, combined with an additional $2.8 million in…

Discussion highlights growing importance on novel ADC payloads, and Akari's ASCO data in KRAS-driven cancers and future potential

CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven cancers  Watch the “What This Means” video here TAMPA, Fla. and LONDON, May 28, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that its CEO…

Discover why Akari Therapeutics PLC (NASDAQ: AKTX) stock is falling on Tuesday after last week's massive 255% rally on positive preclinical cancer data.